At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 800 target
Drug / intervention
zorifertinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
In Brief
An observational study evaluating zorifertinib for EGFR Mutant Advanced Non-small Cell Lung Cancer and Central Nervous System (CNS) Metastases. Currently recruiting, targeting 800 participants across 34 sites.
Detailed Summary
This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS metastases, and to compare the clinical value of zorifertinib with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
N/ARecruiting
2026202720282029203020312032
First PostedAug 2025
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionMay 2031
Study CompletionNov 2031
First PostedAug 27, 2025
Enrollment StartDec 29, 2025
Primary CompletionMay 1, 2031
Study CompletionNov 1, 2031
TodayJul 1, 2026
Enrollment to primary: 5.3 yearsPosted 10 months agoPrimary completion in 4.8 years
Interventions
zorifertinibdrug
Cohort A and B will receive zorifertinib as first line treatment